Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 2

PCE

Kandungan disediakan oleh Practicing Clinicians Exchange. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Practicing Clinicians Exchange atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

2+ y ago 24:00

MP3•Laman utama episod

In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Joleen Hubbard MD

Cathy Eng, MD

Stephanie Andrews, MS, APRN-C

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.

Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.

86 episod

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Practicing Clinicians Exchange #Apps For Education #Np Education #Credit #App Medicine #Pa Education #Np Medicine #Pa Medicine #CE #Apps #CME